Form 4: Shattuck Labs CTO Executes Stock Option Plan

Chief Technical Officer Abhinav A. Shukla exercised options and sold shares under a pre-established Rule 10b5-1 trading plan.

Summary

• Abhinav A. Shukla, Chief Technical Officer of Shattuck Labs, Inc., exercised options for 2,032 shares of common stock at a price of $3.57 per share.
• Following the exercise, the reporting person sold the 2,032 shares at a weighted average price of $7.01 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 2, 2026.
• The primary purpose of the plan is to fund the exercise price and tax withholding obligations associated with option exercises.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative action related to tax obligations and pre-planned equity management.

Positives

• The transaction was executed under a pre-planned Rule 10b5-1 trading plan, indicating a systematic approach to equity management rather than discretionary selling based on non-public information.

Negatives

• The transaction resulted in a net reduction of shares held by the executive, though the volume is relatively small compared to total holdings.

Risks

• Reliance on Rule 10b5-1 plans does not eliminate market risk or the potential for negative perception regarding insider selling.

Future Outlook

The filing does not provide forward-looking business guidance, as it is a routine disclosure of insider equity transactions.

Management Comments

• The plan is intended to execute sales of shares received upon option exercise only as needed to fund the exercise price and estimated tax withholding associated with option exercises under the plan.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is standard practice in the biotechnology sector, where equity-based compensation is a significant component of executive remuneration.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a best-practice standard for corporate officers to avoid potential conflicts of interest or allegations of insider trading.
• The scale of the transaction is consistent with typical tax-funding exercises seen in mid-cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and limited in volume.

Next Steps

• Continued vesting of remaining options through January 25, 2027.

Key Dates

Keywords

Shattuck Labs, STTK, Form 4, Insider Trading, Rule 10b5-1, Biotech